The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over

Last updated: January 18, 2024
Sponsor: Miro Health
Overall Status: Active - Recruiting

Phase

N/A

Condition

Depression

Mild Cognitive Impairment

Dementia

Treatment

N/A

Clinical Study ID

NCT06011681
MH202206MCILLD
  • Ages > 60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • LLD: Age 60 or over; diagnosis of LLD or symptoms consonant with LLD; PHQ-9 score from 15 to 27
  • MCI: Age 60 or over; diagnosis of MCI or self-reported insidious onset and continuedworsening of cognitive decline; intact activities of daily living
  • HC: Age 60 or over

Exclusion

Exclusion Criteria:

  • Age 59 or younger; history of unresolved neurological or psychiatric conditions;current medications known to affect cognition; history of substance abuse; unable toperform activities of daily living; change in employment status due to condition

Study Design

Total Participants: 960
Study Start date:
September 08, 2023
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Miro Health

    Sacramento, California 95816
    United States

    Active - Recruiting

  • Miro Health

    Miami, Florida 33070
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.